<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TAZORAC- tazaroteneÂ gelÂ </strong><br>Allergan, Inc.<br></p></div>
<h1>TAZORAC<span class="Sup">Â®</span><br>(tazarotene) Gel, 0.05%<br>(tazarotene) Gel, 0.1%
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">FOR DERMATOLOGIC USE ONLY<br>NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First"><span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel is a translucent, aqueous gel and contains the compound tazarotene, a member of the acetylenic class of retinoids. It is for topical dermatologic use only. The active ingredient is represented by the following structural formula:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=75145c21-6ef2-455a-8a67-d48ddd4181a4&amp;name=structuralformula.jpg">
</div>
<p>Formula: C<span class="Sub">21</span>H<span class="Sub">21</span>NO<span class="Sub">2</span>S
</p>
<p>Molecular Weight: 351.46
</p>
<p><span class="Bold">Chemical Name:</span> Ethyl 6-[(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate
</p>
<p><span class="Bold">Contains:</span></p>
<p><span class="Bold">Active:</span> Tazarotene 0.05% or 0.1% (w/w)
</p>
<p><span class="Bold">Preservative:</span> Benzyl alcohol 1% (w/w)
</p>
<p><span class="Bold">Inactives:</span> Ascorbic acid; butylated hydroxyanisole; butylated hydroxytoluene; carbomer homopolymer type B; edetate disodium; hexylene glycol; poloxamer 407; polyethylene glycol 400; polysorbate 40; purified water; and tromethamine.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<p class="First">Tazarotene is a retinoid prodrug which is converted to its active form, the cognate carboxylic acid of tazarotene (AGNÂ 190299), by rapid deesterification in animals and man. AGNÂ 190299 (â€œtazarotenic acidâ€?) binds to all three members of the retinoic acid receptor (RAR) family:  RARÎ±, RARÎ², and RARÎ³ but shows relative selectivity for RARÎ², and RARÎ³ and may modify gene expression. The clinical significance of these findings is unknown.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-3.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span>:</span> The mechanism of tazarotene action in <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> is not defined. Topical tazarotene blocks induction of mouse epidermal ornithine decarboxylase (ODC) activity, which is associated with cell proliferation and <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>. In cell culture and <span class="Italics">in vitro</span> models of skin, tazarotene suppresses expression of MRP8, a marker of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> present in the epidermis of <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> patients at high levels. In human keratinocyte cultures, it inhibits cornified envelope formation, whose build-up is an element of the psoriatic scale. Tazarotene also induces the expression of a gene which may be a growth suppressor in human keratinocytes and which may inhibit epidermal hyperproliferation in treated plaques. However, the clinical significance of these findings is unknown.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-3.2"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></span>: The mechanism of tazarotene action in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> is not defined. However, the basis of tazarotene's therapeutic effect in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> may be due to its anti-hyperproliferative, normalizing-of-differentiation and anti-inflammatory effects. Tazarotene inhibited corneocyte accumulation in rhino mouse skin and cross-linked envelope formation in cultured human keratinocytes. The clinical significance of these findings is unknown.
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s6"></a><a name="section-3.3"></a><p></p>
<p class="First"><span class="Bold">Pharmacokinetics:</span> Following topical application, tazarotene undergoes esterase hydrolysis to form its active metabolite, tazarotenic acid. Little parent compound could be detected in the plasma. Tazarotenic acid was highly bound to plasma proteins (greater than 99%). Tazarotene and tazarotenic acid were metabolized to sulfoxides, sulfones and other polar metabolites which were eliminated through urinary and fecal pathways. The half-life of tazarotenic acid was approximately 18 hours, following topical application of tazarotene to normal, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> or psoriatic skin.
</p>
<p>The human <span class="Italics">in vivo</span> studies described below were conducted with tazarotene gel applied topically at approximately 2Â mg/cm<span class="Sup">2</span> and left on the skin for 10 to 12 hours. Both the peak plasma concentration (C<span class="Sub">max</span>) and area under the plasma concentration time curve (AUC) refer to the active metabolite only.
</p>
<p>Two single, topical dose studies were conducted using <span class="Sup">14</span>C-tazarotene gel. Systemic absorption, as determined from radioactivity in the excreta, was less than 1% of the applied dose (without occlusion) in six psoriatic patients and approximately 5% of the applied dose (under occlusion) in six healthy subjects. One non-radiolabeled single-dose study comparing the 0.05% gel to the 0.1% gel in healthy subjects indicated that the C<span class="Sub">max</span> and AUC were 40% higher for the 0.1% gel.
</p>
<p>After 7 days of topical dosing with measured doses of tazarotene 0.1% gel on 20% of the total body surface without occlusion in 24 healthy subjects, the C<span class="Sub">max</span> for tazarotenic acid was 0.72Â Â±Â 0.58Â ng/mL (mean Â± SD) occurring 9Â hours after the last dose, and the AUC<span class="Sub">0-24hr</span> for tazarotenic acid was 10.1Â Â±Â 7.2Â ngÂ·hr/mL. Systemic absorption was 0.91Â Â±Â 0.67% of the applied dose.
</p>
<p>In a 14-day study in five psoriatic patients, measured doses of tazarotene 0.1% gel were applied daily by nursing staff to involved skin without occlusion (8 to 18% of total body surface area; meanÂ Â±Â SD: 13Â Â±Â 5%). The C<span class="Sub">max</span> for tazarotenic acid was 12.0Â Â±Â 7.6Â ng/mL occurring 6Â hours after the final dose, and the AUC<span class="Sub">0-24hr</span> for tazarotenic acid was 105Â Â±Â 55Â ngÂ·hr/mL. Systemic absorption was 14.8Â Â±Â 7.6% of the applied dose. Extrapolation of these results to represent dosing on 20% of total body surface yielded estimates for tazarotenic acid with C<span class="Sub">max</span> of 18.9Â Â±Â 10.6Â ng/mL and AUC<span class="Sub">0-24hr</span> of 172Â Â±Â 88Â ngÂ·hr/mL.
</p>
<p>An <span class="Italics">in vitro</span> percutaneous absorption study, using radiolabeled drug and freshly excised human skin or human cadaver skin, indicated that approximately 4 to 5% of the applied dose was in the stratum corneum (tazarotene: tazarotenic acid =Â 5:1) and 2 to 4% was in the viable epidermis-dermis layer (tazarotene: tazarotenic acid =Â 2:1) 24 hours after topical application of the gel.
</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s7"></a><a name="section-3.4"></a><p></p>
<h2>Clinical Studies
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-3.4.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span>:</span> In two large vehicle-controlled clinical studies, tazarotene 0.05% and 0.1% gels applied once daily for 12Â weeks were significantly more effective than vehicle in reducing the severity of the clinical signs of stable plaque <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> covering up to 20% of body surface area. In one of the studies, patients were followed up for an additional 12Â weeks following cessation of therapy with <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel. Mean baseline scores and changes from baseline (reductions) after treatment in these two studies are shown in the following table:
</p>
<a name="t300"></a><table width="100%">
<caption><span>Plaque Elevation, Scaling, and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span> in Two Controlled Clinical Trials for <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span>
</span></caption>
<col align="left" width="9.021%">
<col align="left" width="6.664%">
<col align="left" width="7.350%">
<col align="left" width="7.350%">
<col align="left" width="7.350%">
<col align="left" width="5.064%">
<col align="left" width="7.029%">
<col align="left" width="7.029%">
<col align="left" width="7.029%">
<col align="left" width="7.029%">
<col align="left" width="7.371%">
<col align="left" width="7.171%">
<col align="left" width="7.371%">
<col align="left" width="7.171%">
<tfoot><tr class="First Last"><td align="left" colspan="14" valign="top"><p class="First Footnote">Plaque elevation, scaling, and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> scored on a 0-4 scale with 0=none, 1=mild, 2=moderate, 3=severe and 4=very severe.<br>B*=Mean Baseline Severity: C-12*=Mean Change from Baseline at end of 12 weeks of therapy:<br>C-24*=Mean Change from Baseline at week 24 (12 weeks after the end of therapy).
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" rowspan="3" valign="middle"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="4" valign="middle">
<span class="Bold">TAZORAC</span><span class="Sup">Â®
</span><span class="Bold">0.05% Gel</span>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="4" valign="middle">
<span class="Bold">TAZORAC</span><span class="Sup">Â®
</span><span class="Bold">0.1% Gel</span>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="4" valign="middle"><span class="Bold">Vehicle Gel</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">Trunk/Arm/Leg<br>Lesions
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">Knee/Elbow<br>Lesions
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">Trunk/Arm/Leg<br>Lesions
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">Knee/Elbow<br>Lesions
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">Trunk/Arm/Leg<br>Lesions
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">Knee/Elbow<br>Lesions
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle">N=108
</td>
<td class="Botrule Rrule" align="center" valign="middle">N=111
</td>
<td class="Botrule Rrule" align="center" valign="middle">N=108
</td>
<td class="Botrule Rrule" align="center" valign="middle">N=111
</td>
<td class="Botrule Rrule" align="center" valign="middle">N=108
</td>
<td class="Botrule Rrule" align="center" valign="middle">N=112
</td>
<td class="Botrule Rrule" align="center" valign="middle">N=108
</td>
<td class="Botrule Rrule" align="center" valign="middle">N=112
</td>
<td class="Botrule Rrule" align="center" valign="middle">N=108
</td>
<td class="Botrule Rrule" align="center" valign="middle">N=113
</td>
<td class="Botrule Rrule" align="center" valign="middle">N=108
</td>
<td class="Botrule Rrule" align="center" valign="middle">N=113
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">Plaque<br>Elevation
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">B*</span><br>C-12*<br>C-24*
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.5</span><br>-1.4<br>-1.2
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.6</span><br>-1.3
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.6</span><br>-1.3<br>-1.1
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.6</span><br>-1.1
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.5</span><br>-1.4<br>-1.1
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.6</span><br>-1.4
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.6</span><br>-1.5<br>-1.0
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.6</span><br>-1.3
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.4</span><br>-0.8<br>-0.9<br><br>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.6</span><br>-0.7<br><br>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.6</span><br>-0.7<br>-0.7<br><br>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.6</span><br>-0.6<br><br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">Scaling
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">B*</span><br>C-12*<br>C-24*
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.4</span><br>-1.1<br>-0.9
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.5</span><br>-1.1
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.5</span><br>-1.1<br>-0.8
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.6</span><br>-0.9
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.4</span><br>-1.3<br>-1.0
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.6</span><br>-1.3
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.5</span><br>-1.2<br>-0.8
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.7</span><br>-1.2
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.4</span><br>-0.7 -0.8<br><br>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.6</span><br>-0.7<br><br>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.5</span><br>-0.6 -0.7<br><br>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.7</span><br>-0.6<br><br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">B*</span><br>C-12*<br>C-24*
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.4</span><br>-1.0<br>-1.1
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.7</span><br>-0.8
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.2</span><br>-0.9<br>-0.7
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.5</span><br>-0.8
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.4</span><br>-1.0<br>-0.9
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.8</span><br>-1.1
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.3</span><br>-1.0<br>-0.8
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.5</span><br>-0.8
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.3</span><br>-0.6<br>-0.7<br><br>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.7</span><br>-0.5<br><br>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.2</span><br>-0.5<br>-0.6<br><br>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Underline">2.5</span><br>-0.5<br><br>
</td>
</tr>
</tbody>
</table>
<p>Global improvement over baseline at the end of 12Â weeks of treatment in these two studies is shown in the following table:
</p>
<table width="100%">
<col align="left" width="23.654%">
<col align="left" width="13.427%">
<col align="left" width="13.427%">
<col align="left" width="12.584%">
<col align="left" width="12.584%">
<col align="left" width="12.341%">
<col align="left" width="11.984%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">TAZORACÂ® 0.05% Gel</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">TAZORACÂ® 0.1% Gel</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Vehicle Gel</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top">N=81
</td>
<td class="Botrule Rrule" align="center" valign="top">N=93
</td>
<td class="Botrule Rrule" align="center" valign="top">N=79
</td>
<td class="Botrule Rrule" align="center" valign="top">N=69
</td>
<td class="Botrule Rrule" align="center" valign="top">N=84
</td>
<td class="Botrule Rrule" align="center" valign="top">N=91
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">100% improvement
</td>
<td class="Botrule Rrule" align="center" valign="top">2 (2%)
</td>
<td class="Botrule Rrule" align="center" valign="top">1 (1%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">1 (1%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">â‰¥75% improvement
</td>
<td class="Botrule Rrule" align="center" valign="top">23 (28%)
</td>
<td class="Botrule Rrule" align="center" valign="top">17 (18%)
</td>
<td class="Botrule Rrule" align="center" valign="top">30 (38%)
</td>
<td class="Botrule Rrule" align="center" valign="top">17 (25%)
</td>
<td class="Botrule Rrule" align="center" valign="top">10 (12%)
</td>
<td class="Botrule Rrule" align="center" valign="top">9 (10%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">â‰¥50% improvement
</td>
<td class="Botrule Rrule" align="center" valign="top">42 (52%)
</td>
<td class="Botrule Rrule" align="center" valign="top">39 (42%)
</td>
<td class="Botrule Rrule" align="center" valign="top">51 (65%)
</td>
<td class="Botrule Rrule" align="center" valign="top">36 (52%)
</td>
<td class="Botrule Rrule" align="center" valign="top">28 (33%)
</td>
<td class="Botrule Rrule" align="center" valign="top">21 (23%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">1-49% improvement
</td>
<td class="Botrule Rrule" align="center" valign="top">21 (26%)
</td>
<td class="Botrule Rrule" align="center" valign="top">32 (34%)
</td>
<td class="Botrule Rrule" align="center" valign="top">18 (23%)
</td>
<td class="Botrule Rrule" align="center" valign="top">23 (33%)
</td>
<td class="Botrule Rrule" align="center" valign="top">27 (32%)
</td>
<td class="Botrule Rrule" align="center" valign="top">32 (35%)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">No change or worse
</td>
<td class="Botrule Rrule" align="center" valign="top">18 (22%)
</td>
<td class="Botrule Rrule" align="center" valign="top">22 (24%)
</td>
<td class="Botrule Rrule" align="center" valign="top">10 (13%)
</td>
<td class="Botrule Rrule" align="center" valign="top">10 (14%)
</td>
<td class="Botrule Rrule" align="center" valign="top">29 (35%)
</td>
<td class="Botrule Rrule" align="center" valign="top">38 (42%)
</td>
</tr>
</tbody>
</table>
<p>The 0.1% gel was more effective than the 0.05% gel, but the 0.05% gel was associated with less local irritation than the 0.1% gel (see <a href="#s23">ADVERSE REACTIONS</a> section).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-3.4.2"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>:</span> In two large vehicle-controlled studies, tazarotene 0.1% gel applied once daily was significantly more effective than vehicle in the treatment of facial <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> of mild to moderate severity. Percent reductions in lesion counts after treatment for 12 weeks in these two studies are shown in the following table:
</p>
<a name="t301"></a><table width="100%">
<caption><span>Reduction in Lesion Counts after Twelve Weeks of Treatment in Two Controlled Clinical Trials for <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>
</span></caption>
<col align="left" width="36.473%">
<col align="left" width="16.477%">
<col align="left" width="17.636%">
<col align="left" width="12.937%">
<col align="left" width="16.477%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">
<span class="Bold">TAZORAC</span><span class="Sup">Â®
</span><span class="Bold">0.1% Gel</span>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Vehicle Gel</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top">N=150
</td>
<td class="Botrule Rrule" align="center" valign="top">N=149
</td>
<td class="Botrule Rrule" align="center" valign="top">N=148
</td>
<td class="Botrule Rrule" align="center" valign="top">N=149
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Noninflammatory lesions
</td>
<td class="Botrule Rrule" align="center" valign="top">55%
</td>
<td class="Botrule Rrule" align="center" valign="top">43%
</td>
<td class="Botrule Rrule" align="center" valign="top">35%
</td>
<td class="Botrule Rrule" align="center" valign="top">27%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Inflammatory lesions
</td>
<td class="Botrule Rrule" align="center" valign="top">42%
</td>
<td class="Botrule Rrule" align="center" valign="top">47%
</td>
<td class="Botrule Rrule" align="center" valign="top">30%
</td>
<td class="Botrule Rrule" align="center" valign="top">28%
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Total lesions
</td>
<td class="Botrule Rrule" align="center" valign="top">52%
</td>
<td class="Botrule Rrule" align="center" valign="top">45%
</td>
<td class="Botrule Rrule" align="center" valign="top">33%
</td>
<td class="Botrule Rrule" align="center" valign="top">27%
</td>
</tr>
</tbody>
</table>
<p>Global improvement over baseline at the end of 12 weeks of treatment in these two studies is shown in the following table:
</p>
<table width="100%">
<col align="left" width="30.126%">
<col align="left" width="16.863%">
<col align="left" width="20.484%">
<col align="left" width="16.863%">
<col align="left" width="15.663%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">
<span class="Bold">TAZORAC</span><span class="Sup">Â®
</span><span class="Bold">0.1% Gel</span>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Vehicle Gel</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top">N=105
</td>
<td class="Botrule Rrule" align="center" valign="top">N=117
</td>
<td class="Botrule Rrule" align="center" valign="top">N=117
</td>
<td class="Botrule Rrule" align="center" valign="top">N=110
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">100% improvement
</td>
<td class="Botrule Rrule" align="center" valign="top">1 (1%)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">â‰¥75% improvement
</td>
<td class="Botrule Rrule" align="center" valign="top">40 (38%)
</td>
<td class="Botrule Rrule" align="center" valign="top">21 (18%)
</td>
<td class="Botrule Rrule" align="center" valign="top">23 (20%)
</td>
<td class="Botrule Rrule" align="center" valign="top">11 (10%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">â‰¥50% improvement
</td>
<td class="Botrule Rrule" align="center" valign="top">71 (68%)
</td>
<td class="Botrule Rrule" align="center" valign="top">56 (48%)
</td>
<td class="Botrule Rrule" align="center" valign="top">47 (40%)
</td>
<td class="Botrule Rrule" align="center" valign="top">32 (29%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">1-49% improvement
</td>
<td class="Botrule Rrule" align="center" valign="top">23 (22%)
</td>
<td class="Botrule Rrule" align="center" valign="top">49 (42%)
</td>
<td class="Botrule Rrule" align="center" valign="top">48 (41%)
</td>
<td class="Botrule Rrule" align="center" valign="top">46 (42%)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">No change or worse
</td>
<td class="Botrule Rrule" align="center" valign="top">11 (10%)
</td>
<td class="Botrule Rrule" align="center" valign="top">12 (10%)
</td>
<td class="Botrule Rrule" align="center" valign="top">22 (19%)
</td>
<td class="Botrule Rrule" align="center" valign="top">32 (29%)
</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s10"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First"><span class="Bold">TAZORAC</span><span class="Sup">Â®</span> (tazarotene) Gel 0.05% and 0.1% are indicated for the topical treatment of patients with stable plaque <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> of up to 20% body surface area involvement.
</p>
<p><span class="Bold">TAZORAC</span><span class="Sup">Â®</span> (tazarotene) Gel 0.1% is also indicated for the topical treatment of patients with facial <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne vulgaris</span> of mild to moderate severity.
</p>
<p>The efficacy of <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel in the treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> previously treated with other retinoids or resistant to oral antibiotics has not been established.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s11"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First">Retinoids may cause fetal harm when administered to a pregnant woman.
</p>
<p>In rats, tazaroteneÂ 0.05% gel, administered <span class="Bold">topically</span> during gestation days 6 through 17 at 0.25Â mg/kg/day (1.5Â mg/m<span class="Sup">2</span>/day) resulted in reduced fetal body weights and reduced skeletal ossification. Rabbits dosed <span class="Bold">topically</span> with 0.25Â mg/kg/day (2.75 mg/m<span class="Sup">2</span> total body surface area/day) tazarotene gel during gestation days 6 through 18 were noted with single incidences of known retinoid malformations, including <span class="product-label-link" type="condition" conceptid="4283381" conceptname="Spina bifida">spina bifida</span>, <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephaly</span>, and heart anomalies. Systemic daily-exposure (AUC<span class="Sub">de</span>) to tazarotenic acid at topical doses of 0.25 mg/kg/day tazarotene in a gel formulation in rats and rabbits represented 0.62 and 6.7 times, respectively, the AUC<span class="Sub">0-24h</span> observed in psoriatic patients treated with 2 mg/cm<span class="Sup">2</span> of  tazarotene gel 0.1% (extrapolated for topical application over a 20% body surface area), and 0.78 and 8.4 times, respectively, the maximum AUC<span class="Sub">0-24h</span> in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients treated with 2 mg/cm<span class="Sup">2</span> of tazarotene gel 0.1% over a 15% (targeted) body surface area.
</p>
<p>As with other retinoids, when tazarotene was given <span class="Bold">orally</span> to experimental animals, <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delays</span> were seen in rats, and teratogenic effects and post-implantation loss were observed in rats and rabbits at AUC<span class="Sub">de</span> values that were 0.55 and 13.2 times, respectively, the AUC<span class="Sub">0-24h</span> observed in psoriatic patients treated with 2 mg/cm<span class="Sup">2</span> of tazarotene gel 0.1% (extrapolated for topical application over a 20% body surface area), and 0.68 and 16.4 times, respectively, the maximum AUC<span class="Sub">0-24h</span> in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients treated with 2 mg/cm<span class="Sup">2</span> of tazarotene gel 0.1% over a 15% (targeted) body surface area.
</p>
<p>In a study of the effect of oral tazarotene on fertility and early embryonic development in rats, decreased number of implantation sites, decreased litter size, decreased numbers of live fetuses, and decreased fetal body weights, all classic developmental effects of retinoids, were observed when female rats were administered 2 mg/kg/day from 15 days before mating through gestation day 7. A low incidence of retinoid-related malformations at that dose was reported to be related to treatment. This dose produced an AUC<span class="Sub">de</span> that was 1.7 times the AUC<span class="Sub">0-24h</span> observed in psoriatic patients treated with 2 mg/cm<span class="Sup">2</span> tazarotene gel 0.1% (extrapolated for topical application over a 20% body surface area) and 2.1 times the maximum AUC<span class="Sub">0-24h</span> in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients treated with 2 mg/cm<span class="Sup">2</span> of tazarotene gel 0.1% over a 15% (targeted) body surface area.
</p>
<p>SYSTEMIC EXPOSURE TO TAZAROTENIC ACID IS DEPENDENT UPON THE EXTENT OF THE BODY SURFACE AREA TREATED. IN PATIENTS TREATED TOPICALLY OVER SUFFICIENT BODY SURFACE AREA, EXPOSURE COULD BE IN THE SAME ORDER OF MAGNITUDE AS IN THESE ORALLY TREATED ANIMALS. ALTHOUGH THERE MAY BE LESS SYSTEMIC EXPOSURE IN THE TREATMENT OF <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">ACNE</span> OF THE FACE ALONE DUE TO LESS SURFACE AREA FOR APPLICATION, TAZAROTENE IS A TERATOGENIC SUBSTANCE, AND IT IS NOT KNOWN WHAT LEVEL OF EXPOSURE IS REQUIRED FOR <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">TERATOGENICITY</span> IN HUMANS (SEE <a href="#s6">CLINICAL PHARMACOLOGY: PHARMACOKINETICS</a>).
</p>
<p>There were thirteen reported pregnancies in patients who participated in clinical trials for topical tazarotene. Nine of the patients were found to have been treated with topical tazarotene, and the other four had been treated with vehicle. One of the patients who was treated with tazarotene cream elected to terminate the pregnancy for non-medical reasons unrelated to treatment. The other eight pregnant women who were inadvertently exposed to topical tazarotene during clinical trials subsequently delivered apparently healthy babies. As the exact timing and extent of exposure in relation to the gestation times are not certain, the significance of these findings is unknown.
</p>
<p><span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, treatment should be discontinued and the patient apprised of the potential hazard to the fetus. Women of child-bearing potential should be warned of the potential risk and use adequate birth-control measures when <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel is used. The possibility that a woman of child-bearing potential is pregnant at the time of institution of therapy should be considered. A negative result for pregnancy test having a sensitivity down to at least 50 mIU/mL for human chorionic gonadotropin (hCG) should be obtained within 2 weeks prior to <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel therapy, which should begin during a normal menstrual period (see also <a href="#s19">PRECAUTIONS: Pregnancy: Teratogenic Effects</a>).
</p>
<p><span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel is contraindicated in individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s12"></a><a name="section-6"></a><p></p>
<h1>WARNINGS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-6.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category X</span>. See <a href="#s11">CONTRAINDICATIONS</a> section. Women of child-bearing potential should be warned of the potential risk and use adequate birth-control measures when <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel is used. The possibility that a woman of child-bearing potential is pregnant at the time of institution of therapy should be considered. A negative result for pregnancy test having a sensitivity down to at least 50Â mIU/mL for hCG should be obtained within 2 weeks prior to <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel therapy, which should begin during a normal menstrual period.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s14"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s15"></a><a name="section-7.1"></a><p></p>
<h2>General
</h2>
<p class="First"><span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel should be applied only to the affected areas. For external use only. Avoid contact with eyes, eyelids, and mouth. If contact with eyes occurs, rinse thoroughly with water. The safety of use of <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel over more than 20% of body surface area has not been established in <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> or <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>.
</p>
<p>Retinoids should not be used on eczematous skin, as they may cause severe irritation.
</p>
<p>Because of heightened burning susceptibility, exposure to sunlight (including sunlamps) should be avoided unless deemed medically necessary, and in such cases, exposure should be minimized during the use of <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel. Patients must be warned to use sunscreens (minimum SPF of 15) and protective clothing when using <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel. Patients with sunburn should be advised not to use <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel until fully recovered. Patients who may have considerable sun exposure due to their occupation and those patients with inherent sensitivity to sunlight should exercise particular caution when using <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel and ensure that the precautions outlined in the Information for Patients subsection are observed.
</p>
<p><span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel should be administered with caution if the patient is also taking drugs known to be photosensitizers (e.g., thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides) because of the increased possibility of augmented <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>.
</p>
<p>Some individuals may experience excessive <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, burning, skin <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> or <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>. If these effects occur, the medication should either be discontinued until the integrity of the skin is restored, or the dosing should be reduced to an interval the patient can tolerate. However, efficacy at reduced frequency of application has not been established. Alternatively, patients with <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> who are being treated with the 0.1% concentration can be switched to the lower concentration.
</p>
<p>Weather extremes, such as <span class="product-label-link" type="condition" conceptid="4221803" conceptname="Flatus">wind</span> or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, may be more irritating to patients using <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s16"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients
</h2>
<p class="First">See attached <a href="#s32">Patient Package Insert</a>.
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s17"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions
</h2>
<p class="First">Concomitant dermatologic medications and cosmetics that have a strong drying effect should be avoided. It is also advisable to "rest" a patient's skin until the effects of such preparations subside before use of <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel is begun.
									</p>
<p>
									In a study of 27 healthy female subjects between the ages of 20â€“55 years receiving a combination oral contraceptive tablet containing 1 mg norethindrone and 35 mcg ethynyl estradiol, concomitant use of tazarotene did not affect the pharmacokinetics of norethindrone and ethynyl estradiol over a complete cycle.
</p>
<p>
The impact of tazarotene on the pharmacokinetics of progestin only oral contraceptives (i.e., minipills) has not been evaluated.
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s18"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">A long-term study of tazarotene following oral administration of 0.025, 0.050, and 0.125Â mg/kg/day to rats showed no indications of increased carcinogenic risks. Based on pharmacokinetic data from a shorter-term study in rats, the highest dose of 0.125 mg/kg/day was anticipated to give systemic exposure (AUC<span class="Sub">de</span>) in the rat equivalent to 0.32 times the AUC<span class="Sub">0-24h</span> observed in psoriatic patients treated with 2 mg/cm<span class="Sup">2</span> of tazarotene gel 0.1% (extrapolated for topical application over a 20% body surface area), and 0.38 times the maximum AUC<span class="Sub">0-24h</span> in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients treated with 2 mg/cm<span class="Sup">2</span> of tazarotene gel 0.1% over a 15% (targeted) body surface area.
</p>
<p>In evaluation of photo co-carcinogenicity, median time to onset of tumors was decreased and the number of tumors increased in hairless mice following chronic topical dosing with intercurrent exposure to ultraviolet radiation at tazarotene concentrations of 0.001%, 0.005%, and 0.01% in a gel formulation for up to 40 weeks.
</p>
<p>A long-term topical application study of up to 0.1% tazarotene in a gel formulation in mice terminated at 88 weeks showed that dose levels of 0.05, 0.125, 0.25, and 1 mg/kg/day (reduced to 0.5 mg/kg/day for males after 41 weeks due to severe dermal irritation) revealed no apparent carcinogenic effects when compared to vehicle control animals; untreated control animals were not completely evaluated. Systemic exposure (AUC<span class="Sub">0-12h</span>) at the highest dose was 2 times the AUC<span class="Sub">0-24h</span> observed in psoriatic patients treated with 2 mg/cm<span class="Sup">2</span> of tazarotene gel 0.1% (extrapolated for topical application over a 20% body surface area), and 2.5 times the maximum AUC<span class="Sub">0-24h</span> in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients treated with 2 mg/cm<span class="Sup">2</span> of tazarotene gel 0.1% over a 15% (targeted) body surface area.
</p>
<p>Tazarotene was found to be non-mutagenic in the Ames assay using <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> and <span class="Italics">E. coli</span> and did not produce structural chromosomal aberrations in a human lymphocyte assay. Tazarotene was also non-mutagenic in the CHO/HGPRT mammalian cell forward gene mutation assay and was non-clastogenic in the <span class="Italics">in vivo</span> mouse micronucleus test.
</p>
<p>No impairment of fertility occurred in rats when male animals were treated for 70 days prior to mating and female animals were treated for 14Â days prior to mating and continuing through gestation and lactation with topical doses of tazarotene gel of up to 0.125Â mg/kg/day. Based on data from another study, the systemic drug exposure (AUC<span class="Sub">de</span>) in the rat would be equivalent to 0.31 times the AUC<span class="Sub">0-24h</span> observed in psoriatic patients treated with 2 mg/cm<span class="Sup">2</span> of tazarotene gel 0.1% (extrapolated for topical application over a 20% body surface area), and 0.38 times the maximum AUC<span class="Sub">0-24h</span> in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients treated with 2 mg/cm<span class="Sup">2</span> of tazarotene gel 0.1% over a 15% (targeted) body surface area.
</p>
<p>No impairment of mating performance or fertility was observed in male rats treated for 70 days prior to mating with oral doses of up to 1 mg/kg/day tazarotene, which produced an AUC<span class="Sub">de</span> that was 0.95 times the AUC<span class="Sub">0-24h</span> observed in psoriatic patients treated with 2 mg/cm<span class="Sup">2</span> of tazarotene gel 0.1% (extrapolated for topical application over a 20% body surface area), and 1.2 times the maximum AUC<span class="Sub">0-24h</span> in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients treated with 2 mg/cm<span class="Sup">2</span> of tazarotene gel 0.1% over a 15% (targeted) body surface area.
</p>
<p>No effect on parameters of mating performance or fertility was observed in female rats treated for 15 days prior to mating and continuing through day 7 of gestation with oral doses of tazarotene up to 2 mg/kg/day. However, there was a significant decrease in the number of estrous stages and an increase in developmental effects at 2 mg/kg/day (see <a href="#s11">CONTRAINDICATIONS</a>). This dose produced an AUC<span class="Sub">0-24h</span> which was 1.7 times that observed in psoriatic patients treated with 2 mg/cm<span class="Sup">2</span> of tazarotene gel 0.1% (extrapolated for topical application over a 20% body surface area), and 2.1 times the maximum AUC<span class="Sub">0-24h</span> in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients treated with 2 mg/cm<span class="Sup">2</span> of tazarotene gel 0.1% over a 15% (targeted) body surface area.
</p>
<p>Reproductive capabilities of F1 animals, including F2 survival and development, were not affected by topical administration of tazarotene gel to female F0 parental rats from gestation day 16 through lactation day 20 at the maximum tolerated dose of 0.125Â mg/kg/day. Based on data from another study, the systemic drug exposure (AUC<span class="Sub">de</span>) in the rat would be equivalent to 0.31 times the AUC<span class="Sub">0-24h</span> observed in psoriatic patients treated with 2 mg/cm<span class="Sup">2</span> of tazarotene gel 0.1% (extrapolated for topical application over a 20% body surface area), and 0.38 times the maximum AUC<span class="Sub">0-24h</span> in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients treated with 2Â mg/cm<span class="Sup">2</span> of tazarotene gel 0.1% over a 15% (targeted) body surface area.
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s19"></a><a name="section-7.5"></a><p></p>
<p class="First"><span class="Bold">Pregnancy</span></p>
<p><span class="Bold">Teratogenic Effects: Pregnancy Category X</span></p>
<p>See <a href="#s11">CONTRAINDICATIONS</a> section. Women of child-bearing potential should use adequate birth-control measures when <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel is used. The possibility that a woman of child-bearing potential is pregnant at the time of institution of therapy should be considered. A negative result for pregnancy test having a sensitivity down to at least 50Â mIU/mL for hCG should be obtained within 2 weeks prior to <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel therapy, which should begin during a normal menstrual period. There are no adequate, well-controlled studies in pregnant women. Although there may be less systemic exposure in the treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> of the face alone due to less surface area for application, tazarotene is a teratogenic substance, and it is not known what level of exposure is required for <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in humans (see <a href="#s6">CLINICAL PHARMACOLOGY: Pharmacokinetics</a>).
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s20"></a><a name="section-7.6"></a><p></p>
<p class="First"><span class="Bold">Nursing Mothers</span></p>
<p>After single topical doses of <span class="Sup">14</span>C-tazarotene to the skin of lactating rats, radioactivity was detected in milk, suggesting that there would be transfer of drug-related material to the offspring via milk. It is not known whether this drug is excreted in human milk. Caution should be exercised when tazarotene is administered to a nursing woman.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s21"></a><a name="section-7.7"></a><p></p>
<p class="First"><span class="Bold">Pediatric Use</span></p>
<p>The safety and efficacy of tazarotene have not been established in pediatric patients under the age of 12 years.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s22"></a><a name="section-7.8"></a><p></p>
<p class="First"><span class="Bold">Geriatric Use</span></p>
<p>Of the total number of subjects in clinical studies of tazarotene gels, 0.05% and 0.1% for plaque <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, 163 were over the age of 65. Subjects over 65 years of age experienced more adverse events and lower treatment success rates after 12 weeks of use of <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel compared with those 65 years of age and younger. Currently there is no other reliable clinical experience on the differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals can not be ruled out. Tazarotene gel for the treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> has not been clinically evaluated in persons over the age of 65.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s23"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<p class="First">In human dermal safety studies, tazarotene 0.05% and 0.1% gels did not induce allergic contact sensitization, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> or photoallergy.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-8.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span>:</span> The most frequent adverse events reported with <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel 0.05% and 0.1% were limited to the skin. Those occurring in 10 to 30% of patients, in descending order, included <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, burning/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, worsening of <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, irritation, and skin <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Events occurring in 1 to 10% of patients included <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span>, irritant <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="135032" conceptname="Dermatitis due to substances taken internally">skin inflammation</span>, fissuring, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>. Increases in â€œpsoriasis worseningâ€? and â€œsun-induced erythemaâ€? were noted in some patients over the 4th to 12th months as compared to the first three months of a 1Â year study. In general, the incidence of adverse events with <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel 0.05% was 2Â to 5% lower than that seen with <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel 0.1%.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-8.2"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>:</span> The most frequent adverse events reported with <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel 0.1% in the treatment of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> occurring in 10Â toÂ 30% of patients, in descending order, included <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span>, burning/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>. Events occurring in 1Â toÂ 10% of patients included irritation, skin <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, fissuring, <span class="product-label-link" type="condition" conceptid="4026047" conceptname="Sacral edema">localized edema</span> and <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e12"></a><a name="section-8.3"></a><p></p>
<p class="First"><span class="Bold">Postmarketing Experience</span></p>
<p>The following adverse reactions have been identified during postmarketing use of <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel 0.05% and 0.1% in clinical practice. Because they are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel. The reactions include: <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span> (including <span class="product-label-link" type="condition" conceptid="4172432" conceptname="Hyperpigmentation of skin">skin hyperpigmentation</span> or <span class="product-label-link" type="condition" conceptid="4041510" conceptname="Skin hypopigmented">skin hypopigmentation</span>), and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s26"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE
</h1>
<p class="First">Excessive topical use of <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel may lead to marked <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>, or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> (see <a href="#s15">PRECAUTIONS: General</a>).
</p>
<p><span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gels 0.05% and 0.1% are not for oral use. Oral ingestion of the drug may lead to the same adverse effects as those associated with excessive oral intake of Vitamin A (<span class="product-label-link" type="condition" conceptid="436941" conceptname="Hypervitaminosis A">hypervitaminosis A</span>) or other retinoids. If oral ingestion occurs, the patient should be monitored, and appropriate supportive measures should be administered as necessary.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s27"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-10.1"></a><p></p>
<p class="First"><span class="Bold">General:</span> Application may cause excessive irritation in the skin of certain sensitive individuals. In cases where it has been necessary to temporarily discontinue therapy, or the dosing has been reduced to a lower concentration (in patients with <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>) or to an interval the patient can tolerate, therapy can be resumed, or the drug concentration or frequency of application can be increased as the patient becomes able to tolerate the treatment. Frequency of application should be closely monitored by careful observation of the clinical therapeutic response and skin tolerance. Efficacy has not been established for less than once daily dosing frequencies.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-10.2"></a><p></p>
<p class="First"><span class="Bold">For <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span>:</span> It is recommended that treatment start with <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> 0.05% Gel, with strength increased to 0.1% if tolerated and medically indicated. Apply <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel once a day, in the evening, to psoriatic lesions, using enough (2Â mg/cm<span class="Sup">2</span>) to cover only the lesion with a thin film to no more than 20% of body surface area. If a bath or shower is taken prior to application, the skin should be dry before applying the gel. If emollients are used, they should be applied at least an hour before application of <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel. Because unaffected skin may be more susceptible to irritation, application of tazarotene to these areas should be carefully avoided. <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel was investigated for up to 12 months during clinical trials for <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-10.3"></a><p></p>
<p class="First"><span class="Bold">For <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>:</span> Cleanse the face gently. After the skin is dry, apply a thin film of <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel 0.1% (2Â mg/cm<span class="Sup">2</span>) once a day, in the evening, to the skin where <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> lesions appear. Use enough to cover the entire affected area. <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel was investigated for up to 12 weeks during clinical trials for <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s31"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First"><span class="Bold">TAZORAC</span><span class="Sup">Â®</span> (tazarotene) Gel is available in concentrations of 0.05% and 0.1%. It is available in a collapsible aluminum tube with a tamper-evident aluminum membrane over the opening and a white propylene screw cap, in 30 g and 100 g sizes.
</p>
<table width="100%">
<col align="left" width="33.333%">
<col align="left" width="33.333%">
<col align="left" width="33.333%">
<tbody class="Headless">
<tr class="First">
<td align="center" valign="top"></td>
<td align="center" valign="top">
<span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel 0.05%
</td>
<td align="center" valign="top">
<span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel 0.1%
</td>
</tr>
<tr>
<td align="center" valign="top">30 g
</td>
<td align="center" valign="top">NDC 0023-8335-03
</td>
<td align="center" valign="top">NDC 0023-0042-03
</td>
</tr>
<tr class="Last">
<td align="center" valign="top">100 g
</td>
<td align="center" valign="top">NDC 0023-8335-10
</td>
<td align="center" valign="top">NDC 0023-0042-10
</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Storage:</span> Store at 25Â°C (77Â°F): excursions permitted to 15-30Â°C (59-86Â°F).
</p>
<p><span class="Bold">Revised: 05/2014</span></p>
<p>Â© 2014 Allergan, Inc.<br>Irvine, CA 92612, U.S.A.<br>Â® marks owned by Allergan, Inc.<br>Made in the U.S.A.
</p>
<p><a name="f02"></a><img alt="Logo
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=75145c21-6ef2-455a-8a67-d48ddd4181a4&amp;name=allerganlogo1.jpg"></p>
<p>71722US14
</p>
<p><span class="Bold">Pharmacist:  Please cut or tear at dotted line and provide this patient package insert to your customer.</span></p>
<p><span class="Bold">--------------------------------------------------------------------------------------------------------------------------------------</span></p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="s32"></a><a name="section-12"></a><p></p>
<p class="First"><span class="Bold">TAZORAC</span><span class="Sup">Â®</span></p>
<p><span class="Bold">(tazarotene) Gel, 0.05%</span></p>
<p><span class="Bold">(tazarotene) Gel, 0.1%</span></p>
<p><span class="Bold">INFORMATION FOR PATIENTS</span></p>
<p><span class="Bold">Please read this leaflet carefully before you start to use your medicine. Read the information you get every time you get more medicine. There may be new information about the drug. This leaflet does not take the place of talks with your doctor. If you have any questions, or are not sure about anything, ask your doctor or pharmacist.</span></p>
<p><span class="Bold">USES</span></p>
<p><span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel 0.05% is used in the treatment of stable plaque <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> covering up to 20% of body surface area.
</p>
<p><span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel 0.1% is used in the treatment of stable plaque <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> covering up to 20% of body surface area and in the treatment of mild to moderately severe facial <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>.
</p>
<p><span class="Bold">BEFORE YOU USE THIS MEDICINE</span></p>
<p>You should be aware that:
</p>
<p>Â  Â  Â  (a) <span class="Bold"> TAZORAC</span><span class="Sup">Â®</span> Gel should not be used if you are pregnant, attempting to become pregnant or at high risk of pregnancy. Consult your physician for adequate birth control measures if you are a female of child-bearing potential. If you are able to become pregnant, take a pregnancy test within 2 weeks prior to beginning to use <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel to be sure you are not pregnant. If you have menstrual periods, begin taking <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel during a normal menstrual period. These actions help assure that you are not pregnant when you begin use.
</p>
<p>Â  Â  Â  (b) <span class="Bold"> TAZORAC</span><span class="Sup">Â®</span> Gel should be used with caution if you are also using other topical agents with a strong skin drying effect, products with high concentrations of alcohol, astringents, spices, the peel of lime, medicated soaps or shampoos, permanent wave solutions, electrolysis, hair depilatories or waxes, or other preparations or processes that might dry or irritate the skin, unless otherwise instructed by your health care practitioner.
</p>
<p>Â  Â  Â  (c) <span class="Bold"> TAZORAC</span><span class="Sup">Â®</span> Gel should not be used if you have sunburn, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span> or other chronic skin condition(s). <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel may cause severe irritation if applied to eczematous skin. If you have sunburn, you should wait until full recovery before using <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel.
</p>
<p>Â  Â  Â  (d) <span class="Bold"> TAZORAC</span><span class="Sup">Â®</span> Gel should not be used if you are inherently sensitive to sunlight.
</p>
<p>Â  Â  Â  (e) <span class="Bold"> TAZORAC</span><span class="Sup">Â®</span> Gel should not be used if you are taking other drugs that increase your sensitivity to sunlight (e.g., thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides). Inform your physician if you are taking any other medications.
</p>
<p>Â  Â  Â  (f) You should use protective clothing and sunscreens with minimum SPF of 15 during the day when being treated with <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel. You should avoid direct sun exposure as much as possible and avoid sunlamps totally while being treated with <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel, unless advised otherwise by your doctor.
</p>
<p>Â  Â  Â  (g) If you have considerable sun exposure due to occupation, particular caution as described above should be exercised when using <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel.
</p>
<p>Â  Â  Â  (h) Weather extremes, such as <span class="product-label-link" type="condition" conceptid="4221803" conceptname="Flatus">wind</span> or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, may be more irritating to your skin while you are using <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel.
</p>
<p><span class="Bold">BEFORE YOU USE THIS MEDICINE</span></p>
<p>Tell your doctor:
</p>
<p>Â  Â  Â  (a) if you are pregnant or are considering becoming pregnant.
</p>
<p>Â  Â  Â  (b) if you are breast-feeding. We do not know if tazarotene can pass through the milk to the baby. The potential harm to the baby is unknown.
</p>
<p>Â  Â  Â  (c) if you are allergic to any ingredients in this medicine.
</p>
<p>Â  Â  Â  (d) if you are already using other products that make your <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">skin dry</span>.
</p>
<p>Â  Â  Â  (e) if you have a skin condition called <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>.
</p>
<p>Â  Â  Â  (f) if you will be subject to excessive sun exposure.
</p>
<p>Â  Â  Â  (g) if you are taking Vitamin A supplements.
</p>
<p><span class="Bold">HOW TO USE THIS PRODUCT</span></p>
<ul class="Disc">
<li>Read the directions on your prescription label carefully. Ask your doctor or pharmacist to explain anything that you do not understand.
</li>
<li>If you become pregnant while using <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel, you should immediately discontinue its use and contact your doctor.
</li>
<li>If you use a cream or lotion to soften or lubricate your skin, apply <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel after ensuring that there is no more cream or lotion on the skin.
</li>
<li>With use of <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel, some people notice a feeling of <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, burning or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>. If irritation is excessive, consult your healthcare provider, who may adjust your medication temporarily to a more comfortable level. Effectiveness of this medication when used less often than once daily has not been proven.
</li>
<li>Do not cover treated areas with dressings or bandages.
</li>
<li>Never use more <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel than instructed and never use it more often than instructed, as application of larger amounts of medication than recommended will not lead to more rapid or better results, and marked <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> may occur.
</li>
<li>Wash your hands after applying the medication unless you are treating your hands for <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>. If the gel accidentally gets on areas you do not need to treat, wash it off.
</li>
<li>Keep <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel away from your eyes, eyelids, and mouth. If it gets in contact with your eyes, wash them with large amounts of cool water, and contact a doctor if <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span> persists.
</li>
</ul>
<p><span class="Bold">MISSED DOSES</span></p>
<p>If you forget or miss a dose of <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel, do not try to "make it up."  Return to your normal application schedule as soon as you can.
</p>
<p><span class="Bold">INSTRUCTIONS SPECIFIC TO TREATMENT OF <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">PSORIASIS</span></span></p>
<ul class="Disc">
<li><p class="First">If you bathe or shower before using <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel, be sure the skin is dry before application. Apply a <span class="Underline">thin film</span> of the gel to your <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> lesions once a day before going to bed.
</p></li>
<li><p class="First">Carefully avoid application to apparently uninvolved skin. <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel may be more irritating to non-lesional skin.
</p></li>
<li><p class="First">If you need to treat your hands, avoid contact with your eyes.
</p></li>
<li><p class="First">Usually your <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> plaques and scales will begin to improve in about one to four weeks, but the <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> may take longer to improve. Continue to use <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel as directed by your doctor.
</p></li>
<li><p class="First">Contact your doctor if your <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> becomes worse.
</p></li>
</ul>
<p><span class="Bold">INSTRUCTIONS SPECIFIC TO TREATMENT OF <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">ACNE</span></span></p>
<ul class="Disc">
<li><p class="First">Gently clean and dry your face before using <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel. Apply <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel once a day, before going to bed, to entire areas of the face where you have <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> lesions. Use enough gel to cover the entire affected area with a <span class="Underline">thin film</span>.
</p></li>
<li><p class="First">Follow your doctor's directions for other routine skin care and the use of make-up. Talk to your doctor about the use of sunscreens and cosmetics, especially those that dry your skin.
</p></li>
<li><p class="First">Usually, your <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> will begin to improve in about 4 weeks. Continue to use <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel for up to 12 weeks as directed by your doctor.
</p></li>
<li><p class="First">Contact your doctor if your <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> becomes worse.
</p></li>
</ul>
<p><span class="Bold">POSSIBLE SIDE EFFECTS OF TAZORAC</span><span class="Sup">Â®
</span><span class="Bold">GEL</span></p>
<p>For patients with <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, the most common side effects of <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel 0.05% and 0.1% are <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, burning/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, red skin, worsening of <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>, irritation, and skin <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.
</p>
<p>For patients with <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, the most common side effects of <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel 0.1% are <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span>, burning/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, red skin, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>.
</p>
<p>Tell your doctor if these side effects become problems. Your doctor may wish to adjust your dose of <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel. However, effectiveness of <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel when used less often than once a day has not been proven.
</p>
<p>While you take <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel, weather extremes, such as <span class="product-label-link" type="condition" conceptid="4221803" conceptname="Flatus">wind</span> or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, may irritate your skin more than usual.
</p>
<p><span class="Bold">WARNINGS</span></p>
<p><span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel should not be used if you are allergic to any of its ingredients. <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel contains tazarotene as the active ingredient, and the following inactive ingredients: ascorbic acid, benzyl alcohol, butylated hydroxyanisole, butylated hydroxytoluene, carbomer homopolymer type B, edetate disodium, hexylene glycol, poloxamer 407, polyethylene glycol 400, polysorbate 40, purified water, and tromethamine.
</p>
<p><span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel should not be used if you are pregnant, attempting to become pregnant or at high risk of pregnancy. Women of child-bearing potential should use adequate birth-control measures when <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel is used.
</p>
<p>If <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel is swallowed by <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span>, contact your doctor or a poison control center.
</p>
<p>Do not use <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel after the expiration date found on the bottom seal of the tube.
</p>
<p>This medicine is for your use only. It can only be prescribed by a doctor. Never give it to anyone else. It may harm them even if their skin problem appears to be the same as yours.
</p>
<p>Retinoids should not be used on eczematous skin, as they may cause severe irritation. Do not use <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel until your doctor has confirmed that your <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span> has fully recovered.
</p>
<p>Because of increased burning susceptibility, exposure to sunlight (including sunlamps) should be avoided or minimized during the use of <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel, unless prescribed differently by your doctor.
</p>
<p>You should use sunscreens (minimum SPF of 15) and protective clothing when using <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel. Be certain that you use these precautions if you expect to experience considerable sun exposure or if you are sensitive to sunlight.
</p>
<p>If you have a sunburn, do not use <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel until you have fully recovered.
</p>
<p>Do not use <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel if you are also taking drugs known to be photosensitizers (e.g.,Â thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides), unless you have discussed taking both drugs with your doctor, because of the increased possibility of a more severe reaction.
</p>
<p><span class="Italics">The safety of use over more than 20% of body surface area has not been established in <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> or <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>.</span></p>
<p><span class="Bold">INSTRUCTIONS FOR USE AND HANDLING:</span>  Keep tube tightly closed when not in use. Store it in a safe place where children cannot reach it. <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel should be stored at 25Â°CÂ (77Â°F): excursions permitted to 15-30Â°C (59-86Â°F).
</p>
<p><span class="Bold">GENERAL ADVICE ABOUT PRESCRIPTION MEDICINES:</span> This medicine is for your use only. Never give it to other people. It may harm them even if their skin problem appears to be the same as yours. Do not use <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel for a condition for which it was not prescribed. Do not use <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel after the expiration date on the bottom seal of the tube.
</p>
<p><span class="Bold">WHERE CAN I GET MORE INFORMATION ABOUT TAZORAC</span><span class="Sup">Â®
</span><span class="Bold">GEL?</span> You can contact Allergan by calling 1-800-433-8871 or by visiting www.tazorac.com. You can ask your doctor or pharmacist for the information about <span class="Bold">TAZORAC</span><span class="Sup">Â®</span> Gel that is written for health professionals.
</p>
<p><span class="Bold">IF YOU HAVE QUESTIONS ABOUT <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">PSORIASIS</span>:</span> Information is available from:
</p>
<p>The National <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">Psoriasis</span> Foundation:
</p>
<p>6600 SW 92nd Avenue, Suite 300, Portland, OR  97223-7195.<br>Telephone:Â 1-800-723-9166 or on the World Wide Web at http://www.<span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>.org.
</p>
<p><span class="Bold">Revised: 05/2014</span></p>
<p>Â© 2014 Allergan, Inc.<br>Irvine, CA 92612, U.S.A.<br>Â® marks owned by Allergan, Inc.<br>Made in the U.S.A.
</p>
<p><a name="f03"></a><img alt="Logo
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=75145c21-6ef2-455a-8a67-d48ddd4181a4&amp;name=allerganlogo2.jpg"></p>
<p>71722US14
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s33"></a><a name="section-13"></a><p></p>
<p class="First">NDC 0023-0042-10
</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">TAZORAC</span><span class="Sup">Â®</span><br>(tazarotene) gel 0.1%
</p>
<p><span class="Bold">100 grams</span></p>
<p>For Dermatologic Use Only<br>Not for Ophthalmic Use
</p>
<p><span class="Bold">ALLERGAN</span><span class="Sup">Â®</span></p>
<div class="Figure">
<a name="f04"></a><img alt="Carton
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=75145c21-6ef2-455a-8a67-d48ddd4181a4&amp;name=carton1.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s34"></a><a name="section-14"></a><p></p>
<p class="First">NDC 0023-8335-10
</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">TAZORAC</span><span class="Sup">Â®</span><br>(tazarotene) gel 0.05%
</p>
<p><span class="Bold">100 grams</span></p>
<p>For Dermatologic Use Only<br>Not for Ophthalmic Use
</p>
<p><span class="Bold">ALLERGAN</span><span class="Sup">Â®</span></p>
<div class="Figure">
<a name="f05"></a><img alt="Carton
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=75145c21-6ef2-455a-8a67-d48ddd4181a4&amp;name=carton2.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TAZORACÂ 		
					</strong><br><span class="contentTableReg">tazarotene gel</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0023-8335</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">CUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>tazarotene</strong> (tazarotene) </td>
<td class="formItem">tazarotene</td>
<td class="formItem">0.5Â mg Â inÂ 1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ascorbic acid</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>butylated hydroxyanisole</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>butylated hydroxytoluene</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARBOMER HOMOPOLYMER TYPE B</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hexylene glycol</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>poloxamer 407</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycol 400</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polysorbate 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>tromethamine</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0023-8335-15</td>
<td class="formItem">15  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3.5 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0023-8335-03</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">30 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0023-8335-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">100 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020600</td>
<td class="formItem">08/01/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TAZORACÂ 		
					</strong><br><span class="contentTableReg">tazarotene gel</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0023-0042</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">CUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>tazarotene</strong> (tazarotene) </td>
<td class="formItem">tazarotene</td>
<td class="formItem">1Â mg Â inÂ 1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ascorbic acid</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>butylated hydroxyanisole</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>butylated hydroxytoluene</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARBOMER HOMOPOLYMER TYPE B</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hexylene glycol</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>poloxamer 407</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycol 400</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polysorbate 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>tromethamine</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0023-0042-03</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0023-0042-15</td>
<td class="formItem">15  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">3.5 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0023-0042-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">100 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020600</td>
<td class="formItem">08/01/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Allergan, Inc.
							(144796497)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Allergan, Inc.</td>
<td class="formItem"></td>
<td class="formItem">362898611</td>
<td class="formItem">MANUFACTURE(0023-8335, 0023-0042)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>07a5c024-17aa-4198-87a7-8db5d0dfcd54</div>
<div>Set id: 75145c21-6ef2-455a-8a67-d48ddd4181a4</div>
<div>Version: 6</div>
<div>Effective Time: 20140707</div>
</div>
</div>Â <div class="DistributorName">Allergan, Inc.</div></p>
</body></html>
